CBLB‐deficient T cells have increased anti‐tumor efficacy, suggesting that CBLB might be exploited as a drug target for the purpose of boosting T‐cell responses against tumors (Hinterleitner et al, 2012). This evidence concerns the gene CBLB and neoplasm.